Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 8236 results

  1. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  2. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  3. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.

  4. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  5. COVID-19 rapid guideline: cystic fibrosis (NG170)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.

  6. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  7. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For children and young people with COVID-19 see our guideline on managing COVID-19

  8. COVID-19 rapid guideline: interstitial lung disease (NG177)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.

  9. COVID-19 rapid guideline: renal transplantation (NG178)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guideline on renal replacement therapy and conservative management and for people with COVID-19 see our guideline on managing COVID-19.

  10. COVID-19 rapid guideline: chronic kidney disease (NG176)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with chronic kidney disease see our guideline on assessing and managing chronic kidney disease and for people with COVID-19 see our guideline on managing COVID-19.

  11. COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.

  12. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on: Depression in adults Depression in adults with a chronic physical health problem Depression in children and young people Generalised anxiety disorder and panic disorder in adults Obsessive-compulsive disorder and body dysmorphic disorder Social anxiety disorder

  13. COVID-19 rapid guideline: vitamin D (NG187)

    This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.

  14. Glaucoma: diagnosis and management (CG85)

    This guidance has been updated and replaced by NICE guideline NG81.

  15. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

    Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.